Argonaut - A deep dive into the BTX 1503 Study Results
(World News Science)

SPEC BUY Thursday, 14 November 2019 Botanix Pharmaceuticals (BOT) Current Price $0.11 Target Price $0.29 A deep dive into the BTX 1503 Study Results Shares on Issue (m): 964.0 Analyst | Michael Eidne Market Cap ($m): 106.0 Quick Read Net Debt / (Cash) ($m): -37.3 Enterprise Value ($m): 68.7 In this report, we take a deep dive into the recently released BTX 1503 phase 2 acne 52 wk High/Low: 0.27 0.07 results. We compare each arm of the study with five other acne products that are either 12m Av Daily Vol (m): 3.42 in development or are fully commercialised. We also review the share price performance Risk adjusted valuation (NPVs): of two other ASX listed biotech stocks, Paradigm (PAR) and...